Monica Plazarte, DO
Endocrinology, Diabetes & Metabolism · Hudson, FLNPI 1073812384
Payments from drug & device makers
Across 852 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Sanofi-aventis U.S. LLC$2K
- Medtronic$2K
- Amgen$2K
- Lilly USA, LLC$2K
- Bayer$2K
- plus $10K from 45 others
What the payments were for
- Speaking & faculty fees$1471%
- Travel & lodging$1,0715%
- Food & beverage$19,80993%
- Education$880%
- Other$1101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,098
- Kerendia$743
- Ozempic$599
- EVENITY$464
- iLet Bionic Pancreas$368
- Korlym$368
- SOLIQUA 100/33$349
- MINIMED 780G$259
- MOUNJARO$239
- FARXIGA$238
- TWIIST$156
- TOUJEO$129
- NEXLIZET$125
- NEXLETOL$125
- Prolia$122
- Veozah$122
- Inpefa$117
- TEPEZZA$112
- FREESTYLE COPILOT$110
- Vascepa$102
How this compares
$21,225 in reported general payments places this provider in the 75th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 343 | $532,487 |
| MounjaroTirzepatide | 191 | $318,085 |
| TrulicityDulaglutide | 175 | $293,976 |
| RybelsusSemaglutide | 83 | $153,546 |
| JardianceEmpagliflozin | 97 | $121,331 |
| JanuviaSitagliptin Phosphate | 95 | $110,378 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 81 | $98,996 |
| Humulin R U-500Insulin Regular, Human | 49 | $96,552 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $92,983 |
| FarxigaDapagliflozin Propanediol | 50 | $74,779 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $67,714 |
| ProliaDenosumab | 32 | $56,186 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $52,847 |
| Teriparatide | 14 | $46,052 |
| KerendiaFinerenone | 33 | $36,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,849 | $716,301490 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,597 | $628,123431 claims |
| Boehringer IngelheimJardiance | $580 | $121,33197 claims |
| MerckJanuvia | $201 | $110,37895 claims |
| AstraZenecaFarxiga | $778 | $74,77950 claims |
| AmgenProlia | $1,741 | $56,18632 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,951 | $39,32637 claims |
| BayerKerendia | $1,553 | $36,73733 claims |
| Johnson & JohnsonInvokana | $122 | $34,87629 claims |
| AbbVieSynthroid | $145 | $10,319106 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $233 | $9,111556 claims |
| IBSA Pharma Inc.Tirosint | $246 | $4,59619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Hudson
- Antonio Pinero PilonaHudson$2M
- Ania JanickaHudson$475K
- Anna Szafran-SwietlikHudson$340K
- Jesus PenabadHudson$160K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.